Our studies further reveal the many facets of IQGAP1’s role in mediating EGF signaling, hence indicating the potential of targeting IQGAP1 for novel anti-cancer therapies that can supplement the existing anti-EGFR chemotherapy. Here, EGFR is linked to cancer.